According to a report by Clipperton finance, the health sciences sector experienced solid growth (100%) in Q2 2013 over the previous quarter with several large deals (>$50M) in "Medtech" and "Biotech".
The health sector accounts for 29% of the total amount invested.
The healthcare sector attracted a significant share of the pie in the second quarter of the year with a growth of 100% with $453M. The IT sector topped the ranking with 62% representing a decrease of 5%. The cleantech sector reached the same level as the previous quarter with 9%.
"In Spain, the sector has also accounted for a similar percentage as investments of Venture capital. In the second quarter there were 26 transactions with €11m of investment. Significant was the sale of Endosense owned by Ysios. A significant round is expected to take place in the coming months. TCD Pharma"Diego Gutierrez, an expert in corporate finance, points out in ABRA INVEST.
Most relevant operations
The largest operation has been carried out by Auris Medical $51M. The round was participated by Sofinnova partners and Sofinnova Ventures. The company will devote the investment to the development of its hearing loss drugs.
In second place comes the operation carried out in Opsona Therapeutics of $43M financed by BB BiotechSunstone, Baxter, Amgen and EMBL Ventures. The company focuses on inflammatory anti-immune diseases.
"In the USA, investment in the sector has accelerated, especially in companies oriented towards the reduction of waste. health costs and optimisation of resources, due to the Affordable Care Act, with which Obama intends to universalise healthcare. 47% of these investments in 2012 went to seed-stage companies," analyses Diego Gutierrez.
EN 
ES